
Canopy acquires Czech Annabis Medical sro
Unter the terms of the agreement, Canopy will pay approximately CAN-$2.5m (€1.6m). Particularly, the company will issue 50,735 common shares valued...

EPO bows to pressure from industry
In a draft paper attached to an invitation to biopharma IP stakeholders for a meeting on 9 February the European Patent Office (EPO) proposes...

Business as usual in Amsterdam
The twelfth annual BIO Europe Spring international partnering conference in rainy Amsterdam was held at the RAI Convention Center. The organisers...

European biotech stocks: 2017 with strong results
Following the more cautious year 2016, the European biotech sector witnessed a significant volume increase in IPOs and follow-on financings in 2017....

Bioeconomy: Bringing in the public
In three years of work, the BioSTEP experts from five European countries organised discussions, workshops, conferences or living lab...

Motif Bio to submit NDA for iclaprim
In the US, 3.6 million patients of this population are hospitalised annually. Motif Bio said the antibiotic may be suitable for first-line...

Santhera’s idebenone not efficient in PPMS patients
It seems not to be a good message for company’s the share value, which had went down from CHF70.95 in September to CHF25.85 this Friday. The...